$NGVT

DYER TERRANCE M sold $34K of NGVT

DYER TERRANCE M (SVP, Chief HR Officer) sold 496 shares of Ingevity Corp (NGVT) at an average of $68.49 ($68.45–$68.57) across 3 trades on 2026-05-28.

Original reporting
SEC EDGAR · DYER TERRANCE M
Published Jun 1, 2026, 6:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NGVT
Neutral
high confidence
Mentioned
$NGVT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NGVTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially.

02

Market read

A small insider sell with limited trading relevance.

03

What to watch

The insider retains a sizable position, indicating continued confidence.

Relevance 3/10Novelty 3/10Timing: filed today

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$NGVTNeutralHigh confidence
Context

SVP and Chief HR Officer Terrance M. Dyer sold 496 shares for $33,970, reducing his stake to 7,202 shares.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

The sale is small relative to float and does not signal material change, but may cause modest short‑term selling pressure.

Market effects

Minimal impact on the specialty chemicals sector.

No regional effect.

Insignificant.

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Ingevity Corp

    Specialty chemicals manufacturer listed on NYSE (NGVT).

  • Terrance M. Dyer

    Senior Vice President and Chief HR Officer, insider.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NGVTMedAI 8/10

Ingevity (NGVT) Q2 2026 Earnings Call Transcript

Ingevity (NGVT) held its Q2 2026 earnings call. Net sales were $314 million, down 5% on reported basis due to the Road Markings divestiture. Adjusted EBITDA rose 14% to $115 million, with margin at 36.6%. Adjusted EPS was $1.74. Free cash flow was $89 million. Full-year guidance for EBITDA and EPS was raised.

$NGVTMedAI 8/10

Ingevity Q2 Earnings Call Highlights

Ingevity (NYSE:NGVT) reported Q2 cash flow excluding a litigation settlement of about $89M, or $2.52/share, with capex near $10M. Performance Materials sales rose 4% to $161M, with segment EBITDA up 6% to $86M and margin to 53.6%. The company raised 2026 outlook to adjusted EBITDA $380M-$400M and EPS $5.00-$5.45, plus free cash flow $220M-$245M.

$NGVTMed

Ingevity reports second quarter 2026 financial results

Ingevity Corp (NGVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Ingevity reports second quarter 2026 financial results Second Quarter 2026 Results and Recent Highlights: • Net sales of $314.1 million decreased 5% from prior year; exc